Trevi Therapeutics Inc., a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis and refractory chronic cough, has appointed Margaret Garin, MD, MSCR, as Vice President of Clinical Development.   Garin will be responsible for progressing the clinical development of Haduvio in chronic cough and brings unique and relevant experience from her previous lead role in clinical de...